FSA Advisors Inc. Purchases New Holdings in Roivant Sciences Ltd. (NASDAQ:ROIV)

FSA Advisors Inc. purchased a new stake in Roivant Sciences Ltd. (NASDAQ:ROIV) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 10,960 shares of the company’s stock, valued at approximately $130,000.

A number of other hedge funds also recently modified their holdings of ROIV. Gladius Capital Management LP acquired a new position in shares of Roivant Sciences in the third quarter valued at $35,000. US Bancorp DE increased its holdings in Roivant Sciences by 146.5% in the 3rd quarter. US Bancorp DE now owns 3,278 shares of the company’s stock valued at $38,000 after buying an additional 1,948 shares during the period. GAMMA Investing LLC raised its stake in shares of Roivant Sciences by 57.0% in the 4th quarter. GAMMA Investing LLC now owns 3,548 shares of the company’s stock valued at $42,000 after buying an additional 1,288 shares in the last quarter. Quarry LP acquired a new stake in shares of Roivant Sciences during the 2nd quarter valued at about $53,000. Finally, Blue Trust Inc. increased its stake in Roivant Sciences by 550.1% in the fourth quarter. Blue Trust Inc. now owns 7,879 shares of the company’s stock valued at $91,000 after acquiring an additional 6,667 shares during the period. Institutional investors own 64.76% of the company’s stock.

Roivant Sciences Stock Up 2.2 %

Shares of ROIV stock opened at $11.37 on Friday. Roivant Sciences Ltd. has a 12-month low of $9.69 and a 12-month high of $13.06. The firm has a 50-day moving average price of $11.72 and a 200 day moving average price of $11.61. The company has a market capitalization of $8.28 billion, a P/E ratio of 2.01 and a beta of 1.27.

Insider Buying and Selling

In related news, Director Sciences Ltd. Roivant bought 16,845,010 shares of the company’s stock in a transaction on Monday, January 13th. The stock was bought at an average cost of $20.00 per share, with a total value of $336,900,200.00. Following the completion of the purchase, the director now owns 96,650,341 shares in the company, valued at approximately $1,933,006,820. The trade was a 21.11 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CIO Mayukh Sukhatme sold 412,584 shares of the stock in a transaction on Wednesday, December 18th. The shares were sold at an average price of $12.05, for a total value of $4,971,637.20. Following the completion of the transaction, the executive now owns 18,836,547 shares in the company, valued at $226,980,391.35. The trade was a 2.14 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 1,942,629 shares of company stock worth $23,034,486 in the last three months. Insiders own 7.90% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright restated a “buy” rating and set a $18.00 price target on shares of Roivant Sciences in a research note on Wednesday, November 13th. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $17.93.

Roivant Sciences Company Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.